Claritas Pharmaceuticals, Inc. (CLAZF)
For informational purposes only. Not financial advice. Analysis by Sedat ANAK, Founder & Editor-in-Chief | AI-powered analysis. Data sourced from SEC filings and institutional-grade financial providers. Editorially reviewed. Not financial advice.
Claritas Pharmaceuticals, Inc. (CLAZF) trades at $0.00 with AI Score 48/100 (Grade C). Claritas Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company focused on developing and commercializing therapies for unmet medical needs. Market cap: $3,659, Sector: Healthcare.
Price live · AI analysis from Jun 15, 2026Analyst Coverage for CLAZF: CLAZF does not currently have published analyst price targets in our coverage universe. This is common for smaller-cap names with limited Wall Street coverage. In the absence of analyst consensus, our AI model evaluates CLAZF against Healthcare peers across nine fundamental dimensions and assigns an underweight signal based on the underlying data.
CLAZF: the 1 perspectives are evenly split.
How is this calculated? →Claritas Pharmaceuticals, Inc. (CLAZF) Healthcare & Pipeline Overview
Claritas Pharmaceuticals, Inc. is a clinical-stage biotechnology firm established in 2014, specializing in developing and commercializing medical therapies for significant unmet patient needs. Operating from San Rafael, California, the company focuses on advancing its pipeline to address critical health challenges within the pharmaceutical sector.
What Is the Investment Thesis for CLAZF?
Claritas Pharmaceuticals, Inc. presents an investment profile centered on its clinical-stage pipeline targeting unmet medical needs within the biotechnology sector. As a company focused on developing novel therapies, its primary value drivers are the successful progression of its drug candidates through clinical trials and eventual regulatory approval. Given its current stage, the company's valuation is heavily influenced by the potential market size of its therapeutic areas and the probability of success for its pipeline assets. Growth catalysts are intrinsically linked to positive clinical trial results, which could significantly de-risk its programs and attract further investment or partnership opportunities. Key milestones would include advancing candidates into later-stage trials (e.g., Phase 2 or Phase 3) and the announcement of favorable data. The company's rebranding in April 2021 signifies a potential strategic realignment or renewed focus, which could underpin future development efforts. However, as a clinical-stage entity with a market capitalization of 4K and a P/E of 0.0, it carries substantial inherent risks, including clinical trial failures, regulatory hurdles, and the need for significant future capital raises. Its OTC Other listing further introduces liquidity and disclosure challenges for investors.
Based on FMP financials and quantitative analysis
CLAZF Key Highlights
- Market Capitalization: $0.00B, indicating a micro-cap or pre-revenue stage company.
- P/E Ratio: 0.00, reflecting the company's current lack of profitability or significant earnings.
- Beta: 1.64, suggesting higher volatility compared to the broader market.
- Employee Count: 3, indicating a very lean operational structure for a clinical-stage pharmaceutical company.
- Dividend Yield: None, consistent with a growth-oriented, clinical-stage biotechnology firm reinvesting all capital into R&D.
Who Are CLAZF's Competitors?
CLAZF is benchmarked below against 8 industry peers on price, market cap, and our AI MoonshotScore.
| Company | Price | Change | Market Cap | AI Score |
|---|---|---|---|---|
| SNDX Syndax Pharmaceuticals, Inc. | $22.11 | +1.33% | $1.96B | 79 |
| ANAB AnaptysBio, Inc. | $63.69 | +0.43% | $2.75B | 79 |
| ABVX Abivax S.A. | $145.38 | +0.51% | $9.53B | 76 |
| CGEN Compugen Ltd. | $2.37 | +3.73% | $223.62M | 76 |
| GLUE Monte Rosa Therapeutics, Inc. | $23.06 | -4.75% | $1.50B | 68 |
| RNAM Avidity Biosciences Inc | $72.86 | +0.05% | $11.26B | 68 |
| DAWN Day One Biopharmaceuticals, Inc. | $21.53 | +0.00% | $2.22B | 68 |
| TLX Telix Pharmaceuticals Limited | $12.15 | +2.36% | $4.12B | 68 |
AI Score by Stock Expert AI · Price data: FMP / Yahoo Finance
What Are CLAZF's Key Strengths?
- Focus on unmet medical needs, addressing areas with high demand.
- Clinical-stage pipeline with potential for novel therapies.
- Lean operational structure with a small, focused team.
- Rebranding in 2021 suggests renewed strategic focus.
What Are CLAZF's Weaknesses?
- Very small employee count (3), indicating limited internal resources.
- Clinical-stage company with no current revenue or profitability (P/E 0.00).
- Market capitalization of 4K, suggesting early development or micro-cap status.
- OTC Other listing, implying lower liquidity and disclosure compared to major exchanges.
What Could Drive CLAZF Stock Higher?
- Positive clinical trial results for pipeline candidates.
- Announcement of strategic partnerships or licensing agreements.
- Progress towards uplisting to a major stock exchange.
- Successful capital raises to fund ongoing R&D and operations.
What Are the Key Risks for CLAZF?
- Financial-distress signal — its Altman Z-Score of -8.30 sits in the distress zone (elevated bankruptcy risk).
- Weak fundamentals — a Piotroski F-Score of 3/9 flags soft profitability, leverage or efficiency.
- High risk of clinical trial failures, common for clinical-stage biotechs.
- Significant capital requirements and potential for future shareholder dilution.
- Intense competition from well-funded pharmaceutical companies.
- Regulatory hurdles and delays in obtaining drug approvals.
- Low liquidity and limited disclosure associated with OTC Other listing.
What Are the Growth Opportunities for CLAZF?
- Advancement of Pipeline Candidates: The primary growth opportunity for Claritas Pharmaceuticals, Inc. lies in the successful progression of its clinical-stage drug candidates through Phase 2 and Phase 3 trials. Positive data from these trials, demonstrating efficacy and safety, would significantly de-risk its assets and increase their commercial viability. For instance, a successful Phase 2 trial could unlock substantial partnership opportunities or attract further investment, potentially leading to a market valuation increase. The timeline for such advancements is typically 2-5 years per phase, with each successful step opening access to a larger potential market for its specific therapeutic area, which could range from hundreds of millions to billions of dollars globally depending on the indication.
- Strategic Partnerships and Collaborations: Given its small employee base and clinical-stage status, forming strategic partnerships with larger pharmaceutical companies or academic institutions represents a significant growth avenue. Such collaborations can provide crucial funding, access to specialized expertise, and established commercialization infrastructure that Claritas currently lacks. A successful partnership could accelerate development timelines, reduce financial burn, and expand the potential market reach of its therapies. These agreements often involve upfront payments, milestone payments, and royalties, providing non-dilutive capital and validating the company's scientific approach, potentially within the next 1-3 years.
- Expansion into New Therapeutic Areas: While currently focused on "unmet medical needs," Claritas Pharmaceuticals, Inc. could explore expanding its research and development efforts into additional therapeutic areas. Leveraging its existing scientific expertise or platform technology, if applicable, to address other high-need conditions could diversify its pipeline and reduce reliance on a single drug candidate or indication. This strategy would broaden its total addressable market and create multiple shots on goal for future revenue generation. Such expansion would typically involve preclinical research and early-stage clinical trials, with a potential timeline of 3-7 years to bring a new program to a significant clinical milestone.
- Uplisting to a Major Exchange: As an OTC Other listed company, Claritas faces challenges related to liquidity and investor perception. A successful uplisting to a major exchange like NASDAQ or NYSE would significantly enhance its visibility, liquidity, and access to institutional capital. This move could attract a broader investor base, potentially leading to a higher valuation and improved trading volume. The process of uplisting requires meeting stringent financial and governance criteria, which could take 1-3 years to achieve, assuming the company can meet the necessary requirements and demonstrate sufficient operational progress.
- Acquisition of Complementary Assets or Technologies: Claritas could pursue the acquisition of complementary drug candidates, intellectual property, or platform technologies from other smaller biotechs or academic spin-offs. Such acquisitions could rapidly expand its pipeline, accelerate its development efforts, or enhance its competitive position by integrating novel approaches. This inorganic growth strategy could provide access to new markets or strengthen its presence in existing ones, potentially leading to a more robust and diversified product portfolio. The timeline for identifying and executing such an acquisition could range from 1-2 years, depending on market opportunities and available capital.
What Opportunities Does CLAZF Have?
- Successful progression of drug candidates through clinical trials.
- Formation of strategic partnerships or licensing agreements.
- Potential for uplisting to a major stock exchange to improve visibility and liquidity.
- Expansion into new therapeutic areas or acquisition of complementary assets.
What Threats Does CLAZF Face?
- High risk of clinical trial failures or adverse regulatory decisions.
- Intense competition from larger pharmaceutical companies and other biotechs.
- Need for significant future capital raises, leading to potential shareholder dilution.
- Market volatility and investor sentiment towards clinical-stage biotechs.
What Are CLAZF's Competitive Advantages?
- Proprietary intellectual property (patents) protecting its drug candidates.
- Specialized scientific expertise in its chosen therapeutic areas.
- Regulatory approvals for its drug candidates, creating barriers to entry for competitors.
- Clinical trial data and results, which are difficult and costly to replicate.
What Does CLAZF Do?
Operating as a clinical-stage specialty pharmaceutical entity, Claritas Pharmaceuticals, Inc. is dedicated to the creation and market introduction of medical therapies addressing significant patient needs that are currently unfulfilled. The company's strategic focus is on identifying and developing innovative treatments for conditions where existing options are limited or inadequate, aiming to improve patient outcomes and quality of life. Established in 2014, the company initially operated under the name Kalytera Therapeutics, Inc. This foundational period involved early-stage research and development efforts, laying the groundwork for its current pipeline. In a significant corporate evolution, the company underwent a rebranding in April 2021, officially changing its name to Claritas Pharmaceuticals, Inc. This rebranding marked a strategic pivot or a clearer articulation of its mission and therapeutic focus. Its corporate headquarters are located in San Rafael, California, serving as the central hub for its operations, which include managing its clinical development programs and strategic partnerships. As a clinical-stage company, Claritas Pharmaceuticals, Inc. is primarily engaged in the rigorous process of bringing potential new drugs through various phases of clinical trials, from initial safety assessments to efficacy studies in patient populations. This involves substantial investment in research, regulatory compliance, and scientific expertise, all geared towards eventually securing regulatory approvals for its therapeutic candidates. The company's small employee base of three individuals suggests a lean operational model, likely relying on outsourced research, contract manufacturing organizations, and strategic collaborations to advance its pipeline. This structure is common among early-stage biotechnology firms, allowing for flexibility and focused resource allocation on core R&D activities. The ultimate goal is to address critical medical gaps and deliver novel pharmaceutical solutions to the market.
What Products and Services Does CLAZF Offer?
- Develops and commercializes medical therapies.
- Focuses on addressing significant unmet patient needs.
- Operates as a clinical-stage specialty pharmaceutical entity.
- Conducts research and development for new drug candidates.
- Manages clinical trials for its therapeutic pipeline.
- Aims to introduce novel treatments to the market.
- Headquartered in San Rafael, California.
How Does CLAZF Make Money?
- Primarily focused on research and development of drug candidates.
- Future revenue generation is contingent on successful clinical trials, regulatory approvals, and commercialization of therapies.
- Potential for revenue through licensing agreements, milestone payments, and royalties from partnerships.
- Currently relies on capital raises to fund its operations and R&D activities.
What Industry Does CLAZF Operate In?
Claritas Pharmaceuticals, Inc. operates within the highly specialized and capital-intensive biotechnology industry, a segment of the broader healthcare sector. This industry is characterized by long development cycles, significant R&D expenditures, and high regulatory hurdles. The company's focus on "unmet medical needs" aligns with a major trend in pharmaceuticals, where innovation is driven by addressing conditions lacking effective treatments. The competitive landscape is intense, featuring both large pharmaceutical companies with vast resources and numerous smaller, clinical-stage biotechs vying for breakthrough discoveries. Claritas, with its lean structure and clinical-stage pipeline, positions itself as an innovator seeking to carve out niche markets by developing novel therapies. Its success will depend on its ability to navigate the complex clinical trial process, secure intellectual property, and differentiate its potential products in a crowded market. The industry is also subject to evolving scientific understanding and technological advancements, which can rapidly shift therapeutic paradigms.
Who Are CLAZF's Key Customers?
- Ultimately, patients suffering from conditions with unmet medical needs.
- Healthcare providers (doctors, hospitals) who prescribe and administer treatments.
- Pharmaceutical distributors and pharmacies.
- Potential pharmaceutical partners for licensing or co-development agreements.
Company Profile
Claritas Pharmaceuticals, Inc. operates in the Biotechnology industry within the Healthcare sector. It is headquartered in San Rafael, US. The company is led by CEO Robert Farrell. CLAZF has traded publicly since 2016.
F-Score 3/9Financial Health
Claritas Pharmaceuticals, Inc.'s Piotroski F-Score is 3/9, a 9-point checklist of profitability, leverage and efficiency — flagging fundamental weakness worth scrutiny. Its Altman Z-Score of -8.30 places it in the distress zone, a signal of elevated financial risk.
P/E 0.0Key Financial Metrics
Return on assets is 40.3%, showing how much profit it generates from its asset base. CLAZF trades at a trailing price-to-earnings ratio of 0.00, below the Healthcare sector average of ~23x. A current ratio of 0.14 means current liabilities exceed short-term assets, a liquidity point worth watching.
CLAZF Valuation & Market Position
With a 4K market cap, Claritas Pharmaceuticals, Inc. sits in the micro-cap segment of the market. Relative to its peer group, CLAZF's quantitative score of 48/100 is below the peer average of 76/100.
FY2026 estForward Outlook
Wall Street analysts project Claritas Pharmaceuticals, Inc. revenue of about $0 for fiscal 2026, with EPS near $-0.29.
CLAZF Financials
Fundamental Snapshot
Based on FMP financials and quantitative analysis
Bull Case vs Bear Case
Bull Case
- Focus on unmet medical needs, addressing areas with high demand.
- Clinical-stage pipeline with potential for novel therapies.
- Lean operational structure with a small, focused team.
- Rebranding in 2021 suggests renewed strategic focus.
Bear Case
- Very small employee count (3), indicating limited internal resources.
- Clinical-stage company with no current revenue or profitability (P/E 0.00).
- Market capitalization of 4K, suggesting early development or micro-cap status.
- OTC Other listing, implying lower liquidity and disclosure compared to major exchanges.
AI-generated arguments based on insider flow, news sentiment and technicals — not financial advice · July 2026
CLAZF Latest News
No recent news available for CLAZF.
CLAZF Analyst Consensus
Consensus Rating
Aggregated Buy/Hold/Sell recommendations from Benzinga, Yahoo Finance, and Finnhub for CLAZF.
Price Targets
Wall Street price target analysis for CLAZF.
CLAZF MoonshotScore
What does this score mean?
The MoonshotScore rates CLAZF's growth potential on a scale of 0-100 across multiple factors including innovation, market disruption, financial health, and momentum.
Leadership: Robert Farrell
Chief Executive Officer
Unknown
Track Record: Unknown
CLAZF OTC Market Information
The OTC Other tier, also known as the Pink Sheets, is the lowest and most speculative tier of the over-the-counter market. Unlike companies listed on major exchanges such as NYSE or NASDAQ, which have stringent listing requirements regarding financial health, corporate governance, and minimum share prices, companies on OTC Other have minimal to no disclosure requirements. This tier is not a reporting exchange and includes companies that may not be current in their reporting or have limited public information. This contrasts sharply with the robust regulatory oversight and transparency mandated for companies on national exchanges, which provide investors with standardized, timely financial data and greater liquidity.
- OTC Tier: OTC Other
- Disclosure Status: Unknown
- Limited public information and disclosure, making due diligence challenging.
- Significantly lower liquidity and wider bid-ask spreads compared to major exchanges.
- Increased susceptibility to market manipulation due to less regulatory oversight.
- Difficulty in obtaining reliable price quotes and executing trades efficiently.
- Potential for delisting or further restrictions if disclosure status remains unknown or inadequate.
- Verify the company's current financial statements and audit reports, if any are available.
- Research any available news, press releases, or corporate filings from reliable sources.
- Assess the company's business model, pipeline, and intellectual property claims thoroughly.
- Investigate the background and track record of management and board members.
- Understand the specific regulatory environment and clinical trial progress for its therapies.
- Evaluate the company's capital structure, outstanding shares, and potential for dilution.
- Consult with a financial advisor experienced in OTC markets.
- Established in 2014, indicating a history beyond a recent shell company.
- Rebranded in April 2021, suggesting active corporate management and strategic intent.
- Identified headquarters location in San Rafael, California.
- Focus on a specific industry (Biotechnology) and mission (unmet medical needs).
Common Questions About CLAZF (Healthcare)
What is Claritas Pharmaceuticals, Inc.'s primary focus in the biotechnology sector?
Claritas Pharmaceuticals, Inc. is a clinical-stage specialty pharmaceutical company primarily focused on the research, development, and eventual commercialization of medical therapies designed to address significant unmet patient needs. This means the company targets diseases and conditions where current treatment options are either ineffective, limited, or non-existent. Its strategy involves advancing drug candidates through various phases of clinical trials, aiming to bring innovative solutions to market. The company operates with a lean structure, suggesting a focus on core R&D activities and potentially leveraging external partnerships for broader development and commercialization efforts within the highly specialized biotechnology landscape.
How does Claritas Pharmaceuticals, Inc. manage the inherent risks of clinical-stage drug development?
As a clinical-stage pharmaceutical company, Claritas Pharmaceuticals, Inc. faces substantial inherent risks, including the high probability of clinical trial failures, extended development timelines, and significant capital requirements. While specific risk management strategies beyond its core focus on unmet needs are not detailed in the provided data, typical approaches in this sector include rigorous preclinical research, careful selection of drug candidates with strong scientific rationale, and strategic partnerships to share development costs and risks. The company's lean operational model may also allow for focused resource allocation, but it also implies a reliance on external expertise and funding to navigate the complex and costly drug development process from discovery to potential market approval.
What are the implications of Claritas Pharmaceuticals, Inc. trading on the OTC Other market?
Trading on the OTC Other market, also known as the Pink Sheets, carries several implications for Claritas Pharmaceuticals, Inc. and its investors. This tier has minimal to no disclosure requirements, leading to an "Unknown" disclosure status, which can make it challenging for investors to access comprehensive financial and operational information. Consequently, the stock typically experiences lower liquidity, wider bid-ask spreads, and increased price volatility compared to companies on major exchanges like NASDAQ or NYSE. This can make it difficult to buy or sell shares efficiently. Investors should be aware of these inherent risks, including potential for market manipulation and reduced transparency, when considering an investment in an OTC Other listed company.
What are the key factors to evaluate for CLAZF?
Claritas Pharmaceuticals, Inc. (CLAZF) holds an AI score of 48/100 (low). P/E: 0.0x vs the S&P 500's ~20-25x. Not financial advice.
How frequently does CLAZF data refresh on this page?
CLAZF prices update in real time during U.S. market hours. Fundamentals refresh after quarterly filings; analyst ratings and AI insights update daily; news is aggregated continuously.
What has driven CLAZF's recent stock price performance?
Claritas Pharmaceuticals, Inc. (CLAZF) moves on earnings results, analyst revisions, sector rotation, and market sentiment. Notable catalyst: Focus on unmet medical needs, addressing areas with high demand. See the News tab for the latest drivers. Past performance does not predict future results.
Should investors consider CLAZF overvalued or undervalued right now?
Claritas Pharmaceuticals, Inc. (CLAZF) trades at 0.0x earnings. Compare P/E, P/S, and EV/EBITDA against sector peers for a full view.
What research should beginners do before buying CLAZF?
Before investing in Claritas Pharmaceuticals, Inc. (CLAZF), research these four areas: (1) the company's revenue model and competitive position (see Company Overview), (2) financial health through revenue growth, margins, and cash flow (see MoonshotScore), (3) what Wall Street analysts recommend and their price targets (see Analyst tab), and (4) specific risk factors that could impact the stock (see Risk Factors section).
Disclaimer: This content is for informational purposes only and does not constitute investment advice. Always do your own research and consult a financial advisor.
Official Resources
Data provided for informational purposes only.
- All information is derived directly from the provided source data.
- Specific details regarding CEO background, track record, and full product pipeline were not available in the source data and are noted as 'Unknown'.